Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Cholangiocarcinoma · Hilar Cholangiocarcinoma · Bile Duct Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Contact: Study coordinator (Jinbo MD, doctor) · jbyue@sdfmu.edu.cn · 053167626442

Study leads

Jinbo Yue
Principal Investigator
Shandong Cancer Hospital and Institute
Bo Zhang
Study Chair
Shandong Cancer Hospital and Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Cancer, Metastatic · Cancer · Cancer of Pancreas

Abroad (travel likely)Recruiting

Birmingham, United States · Mobile, United States

Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Naples, Italy · Naples, Italy

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Pancreatic Adenocarcinoma · Cholangiocarcinoma · Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Wuhan, China